Epitalon

Epitalon (also spelled Epithalon) is a short synthetic peptide marketed in longevity research circles for anti-aging effects, based on a proposed 'telomerase activation' idea — that it can lengthen telomeres, the protective caps on chromosomes tied to cellular aging. It's a Khavinson bioregulator peptide made from a pineal-gland extract, developed in Russia, and outside Russia it's sold only as a research peptide, not an approved drug in the US or other major Western countries. Nearly all the supporting evidence comes from one Russian research tradition with limited independent replication, so the jump from cell-culture findings to real anti-aging effects in people isn't well established.

Epitalon is marketed for anti-aging, based mainly on telomere and telomerase effects. In cell-culture work it increased telomerase activity and telomere length in human cells, and a 2025 independent UK replication reported similar effects. Russian clinical reports over several decades describe effects on aging biomarkers, but the leap from cell-culture findings to anti-aging effects in people is large and not well validated, and most work comes from a single research tradition with limited independent replication.

Not FDA approved for any indication. Not approved as a pharmaceutical drug in any major regulatory jurisdiction outside Russia (FDA, EMA, MHRA, TGA, Health Canada). Reviewed for possible inclusion on the Section 503A compounding Bulks List, with no FDA determination issued — the Pharmacy Compounding Advisory Committee met on July 24, 2026 (Federal Register 91 FR 20465; docket FDA-2025-N-6895) and took separate votes on Epitalon free base and Epitalon acetate, the use evaluated by FDA being insomnia. FDA's pre-meeting briefing document proposed that neither form be included. FDA has published no summary minutes, vote results, or determination from that meeting as of 2026-09-03, and a PCAC recommendation is advisory and non-binding, so 503A compounding is not permitted on that basis; Epitalon is not on the 503A Bulks List. Available in Russia and several Eastern European countries via the Khavinson short-peptide bioregulator framework developed at the St. Petersburg Institute of Bioregulation and Gerontology since the 1970s. Available in Western markets as a research peptide. Not listed in the WADA 2026 Prohibited List. Not-named is not not-prohibited: WADA's S0 (Non-Approved Substances) prohibits at all times any pharmacological substance "with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development)", which describes this compound — so S0 captures it by default and it is off-limits in drug-tested sport. Verified against the local archive `docs/legal/wada-2026-prohibited-list.txt` (S0 clause + full-text search returning no hit) on 2026-09-07. Not a DEA-scheduled controlled substance. Sister compound to Pinealon; both are Khavinson short peptides associated with pineal gland function; Epitalon's most-cited distinguishing feature is the proposed telomerase-activation mechanism that has driven its prominence in research-community longevity protocols.

Epitalon is not FDA-approved and its long-term safety in humans is not established outside the Russian clinical experience; the telomerase- related mechanism is a specific theoretical caution for anyone with cancer or a strong cancer family history. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

⚠️ For research and educational purposes only. Epitalon is not approved by the FDA or any major Western regulatory agency as a pharmaceutical drug for any indication. Information in this entry is informational, not medical advice. Always confirm dose calculations and consult appropriate professional guidance before any protocol decisions.

⚠️ The Khavinson short-peptide framework is concentrated within a single research tradition with limited independent replication. Same Khavinson framework discussion as Pinealon applies — most published work comes from Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, with limited independent replication outside that research tradition. This is structurally similar to but more extreme than the BPC-157 / Sikiric-lab citation-concentration pattern flagged elsewhere in the library. Researchers should be explicit with themselves about the asymmetric evidence base — strong claims (notably the telomerase-activation framing that has driven Epitalon's prominence) rest on a narrow research tradition.

⚠️ The "telomerase activation" claim is the dominant research-community framing — and is the strongest claim in the Epitalon evidence base. The most-cited Epitalon mechanism in research-community materials is upregulation of telomerase enzyme activity in mammalian cell lines, leading to telomere length extension. This claim has been demonstrated in published Khavinson-group cell-culture work[¹] and in some recent independent replication attempts.[²] However, the translation from cell culture telomerase upregulation to human anti-aging effects is large and not well-validated — telomere length is one of many factors in cellular aging, and clinical translation of telomere-modulating interventions has been historically difficult. Researchers should interpret the "telomerase activation" framing as a real mechanistic finding at the cell-culture level whose human clinical relevance is uncertain.

⚠️ Sequence note: AEDG (Ala-Glu-Asp-Gly), four amino acids. Epitalon is a tetrapeptide with the sequence Alanine-Glutamic acid-Aspartic acid-Glycine (Ala-Glu-Asp-Gly; single-letter code AEDG). Some research-community materials refer to Epitalon by alternative sequence representations or use the related parent compound name "Epithalamin" (a polypeptide pineal extract) interchangeably. Researchers should confirm the specific sequence with their source — AEDG is the canonical Epitalon sequence in the Khavinson published literature; alternative sequences (e.g., variants with proline substitutions) are different compounds.

⚠️ Cycling and course-based use are the dominant research-community pattern. Unlike daily injectable peptides used for months or years in research-community protocols, Khavinson peptides including Epitalon are typically dosed in discrete 10–20-day courses with extended off-periods (typically 30–180 days) between courses. This pattern reflects the Russian clinical use framework and the proposed mechanism — the gene-expression modulation effects are claimed to persist beyond the dosing window, with the off-periods preventing tolerance and allowing the cellular effects to consolidate. Researchers using continuous daily Epitalon outside the course-based pattern are operating outside the published Khavinson framework.

Epitalon (AEDG) is a synthetic tetrapeptide developed by the Vladimir Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, beginning in the late 1970s. The compound was identified through fractionation of epithalamin, a polypeptide extract of the bovine pineal gland — Epitalon (AEDG) is the synthetic short peptide that retains the proposed pineal-targeted bioregulatory activity. Among the dozen or so Khavinson short-peptide bioregulators, Epitalon is the most-recognized in Western research-community contexts because of its telomerase activation framing — a mechanism claim that has driven sustained research-community interest in longevity and "anti-aging" protocols.

Khavinson framework — see Pinealon entry. The historical and structural context for Epitalon (Russian gerontology research tradition, St. Petersburg Institute, peptide-DNA interaction hypothesis, oral bioavailability claims, course-based dosing) parallels Pinealon; see the [Pinealon entry's About section](./pinealon.md) for the cluster-level framework discussion. Researchers should hold the Khavinson mechanism framework loosely — strong claims rest on a narrow research tradition with limited independent replication.

Mechanism — telomerase activation (the dominant research-community claim). The most-cited Epitalon mechanism is upregulation of telomerase enzyme activity in mammalian cells, leading to extension of telomere length over multiple cell divisions. The original Khavinson-group cell-culture work demonstrated that Epitalon administration in human somatic cell cultures induced telomerase activity and telomere lengthening above the Hayflick limit normally observed.[¹] More recent independent replication attempts have shown either telomerase upregulation or activation of the alternative ALT (alternative lengthening of telomeres) pathway in some human cell lines.[²] The cell-culture telomerase finding appears reasonably robust; the clinical translation to anti-aging effects in humans is large and not well-validated.

Mechanism — pineal/melatonin axis modulation. Epitalon is also reported to restore age-related decline in melatonin secretion by the pineal gland, with effects documented in aged primate and limited human work. This melatonin-restoration framing is mechanistically distinct from the telomerase activation framing but shares the pineal-targeted cellular framework. Some published Khavinson-group work has reported that Epitalon affects mRNA levels of interleukin-2, modulates thymocyte mitogenic activity, and enhances activity of multiple enzymes (acetylcholinesterase, butyrylcholinesterase, telomerase).[¹]

Mechanism — gene-expression modulation (Khavinson framework). Per the broader Khavinson hypothesis covered in the [Pinealon entry](./pinealon.md), Epitalon is proposed to act via direct peptide-DNA interaction modulating tissue-specific gene expression in pineal and broader CNS contexts. The framing is contested in mainstream molecular biology; the practical implication is that Epitalon's claimed effects across multiple biological systems (pineal, immune, cellular aging) are unified under the Khavinson hypothesis but are difficult to reconcile with mainstream pharmacology.

Russian clinical use — multi-decade experience. Epitalon (and its parent extract Epithalamin) has been studied and used in Russian clinical settings for over 30 years. The Russian clinical use base includes long-term gerontology trials in elderly cohorts with reports of beneficial effects on multiple biomarkers of aging (immune function, cardiovascular function, sleep quality, lifespan). The most-cited Russian clinical Epitalon work is from the Khavinson group itself; independent replication outside the Khavinson research tradition is limited.

Common research interests. Epitalon's research-community use spans: - Longevity / "anti-aging" protocols — the dominant research-community use, driven by the telomerase-activation framing. Researchers report subjective improvements in general "vitality", sleep quality, and skin/hair condition over multi-course annual protocols. - Sleep / circadian rhythm support — the pineal-gland association makes Epitalon a research-community choice for sleep protocols, often paired with conventional melatonin or sleep-supportive supplements. - Stack with Pinealon for "Khavinson pineal protocol" — the canonical pairing within the Khavinson framework. - Stack with other longevity-focused interventions — in research-community longevity protocols Epitalon is sometimes stacked with NAD+ precursors, rapamycin, metformin, or other pharmacologic interventions targeting cellular aging mechanisms.

Regulatory status — under active FDA review. Research peptide outside Russia; not FDA approved for any indication. Epitalon is not currently on the FDA Section 503A compounding Bulks List, and it is under active FDA review for possible inclusion: it was on the agenda of the Pharmacy Compounding Advisory Committee meeting held July 24, 2026, where the committee voted separately on the free base and the acetate, and FDA's pre-meeting briefing document proposed against adding either, citing that the substance is not well characterized, has little or no human efficacy evidence for the nominated routes, has insufficient human safety data, and carries unassessed immunogenicity risk. FDA has published no minutes, vote results, or final determination as of 2026-09-03; a committee recommendation is advisory and non-binding, so Epitalon remains off the 503A Bulks List and not compoundable on that basis. The committee's vote has not been published by FDA, so researchers should check the FDA pcac meeting-materials page and the Federal Register directly rather than rely on secondary reporting.[⁵] Note the framing mismatch: the use FDA evaluated is insomnia, not the telomerase/anti-aging framing that dominates research-community discussion of Epitalon and this entry. Epitalon is not listed in WADA 2026[⁴] and is not a DEA-scheduled controlled substance. Not-named is not not-prohibited: WADA's S0 (Non-Approved Substances) prohibits at all times any pharmacological substance "with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development)", which describes this compound — so S0 captures it by default and it is off-limits in drug-tested sport. Verified against the local archive `docs/legal/wada-2026-prohibited-list.txt` (S0 clause + full-text search returning no hit) on 2026-09-07.

Commonly reported

• Injection site reactions (with subcutaneous use) — uncommon
• Mild GI symptoms (with oral use) — uncommon
• Occasional headache (uncommon)
• No reported tolerance, dependence, or withdrawal syndrome at the course-based dosing pattern
• No consistent pattern of serious adverse events in the published Khavinson-group or Russian clinical literature
• Long-term safety in Western populations is essentially unknown. No multi-year independent human safety dataset exists outside the Russian clinical experience.
• Active malignancy — caution, with the same theoretical concern as for Pinealon. The telomerase activation mechanism is specifically concerning in the context of cancer because telomerase upregulation is a hallmark of many cancer cells, and pharmacological telomerase activation is theoretically problematic for cellular populations with pre-existing genomic instability. Researchers with active cancer or strong cancer family history should be particularly cautious about Epitalon's telomerase claim.
• Drug interactions are uncharacterized.
• Pregnancy and lactation safety — no data; default to contraindicated.

Pregnancy and lactation: no data; default to contraindicated

Pediatric use: no data outside specific Russian clinical contexts — should not be used in researchers under 18

Active malignancy or strong cancer family history — specific theoretical caution given the telomerase-activation mechanism. Telomerase upregulation is a feature of most cancer cells; pharmacological activation is theoretically problematic in cellular populations with pre-existing genomic instability.

Active immunosuppressive therapy — caution; Khavinson peptides are sometimes claimed to have immune-modulating effects.

Known peptide allergy or hypersensitivity — contraindicated.

Regulatory note (US): Epitalon is sold as a research peptide and is not FDA approved. It is not currently on the FDA Section 503A compounding Bulks List and is under active FDA review — reviewed at the Pharmacy Compounding Advisory Committee meeting of July 24, 2026 (evaluated use: insomnia), where FDA's pre-meeting briefing recommended against inclusion; FDA has published no minutes, vote results, or determination as of 2026-09-03, so Epitalon remains off the 503A Bulks List and not compoundable on that basis; a committee recommendation is advisory and non-binding.[⁵]

Regulatory note (DEA): Epitalon is not a DEA-scheduled controlled substance.

Regulatory note (WADA): Epitalon is not listed in the 2026 WADA Prohibited List. Not-named is not not-prohibited: WADA's S0 (Non-Approved Substances) prohibits at all times any pharmacological substance "with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development)", which describes this compound — so S0 captures it by default and it is off-limits in drug-tested sport. Verified against the local archive `docs/legal/wada-2026-prohibited-list.txt` (S0 clause + full-text search returning no hit) on 2026-09-07.[⁴]

Khavinson bioregulator

A class of short peptides from a Russian/Soviet research program proposed to act as tissue-specific regulators; far less studied in Western literature.

Telomerase

An enzyme that can lengthen telomeres, the protective caps on the ends of chromosomes.

Peptide

A short chain of amino acids, the building blocks of proteins. Many compounds in this library are peptides.

Subcutaneous

An injection into the fatty layer just under the skin, rather than into a muscle or vein.

Western clinical trial

A study run to the evidence standards used by regulators like the FDA (randomized, controlled, peer-reviewed).

1. Khavinson VKh, Bondarev IE, Butyugov AA. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 135(6):590-2. doi: 10.1023/a:1025493705728.(PMID 12937682)
2. Al-Dulaimi S, Thomas R, Matta S, Roberts T. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 26(5):178. doi: 10.1007/s10522-025-10315-x.(PMID 40908429)
3. Khavinson VKh, Morozov VG. (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters, 24(3-4):233-40.(PMID 14523363)
4. World Anti-Doping Agency. The 2026 Prohibited List, International Standard (effective 1 January 2026). Canonical PDF: wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (local archival copy in `docs/legal/wada-2026-prohibited-list.pdf`). Epitalon is not listed in the 2026 WADA Prohibited List. S0 note (2026-09-07): not-named is confirmed, but this compound has no approval as a medicine anywhere, so WADA's S0 (Non-Approved Substances) captures it by default — the negative listing rules out a named prohibition, not prohibition.
5. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026 — Epitalon (free base) and Epitalon acetate reviewed on Day 2 (July 24, 2026); use evaluated by FDA: insomnia. FDA meeting page: fda.gov — July 23–24, 2026 PCAC meeting. Federal Register notice of meeting: 91 FR 20465 (published 2026-04-16), FR Doc. 2026-07361, docket FDA-2025-N-6895 (public comment docket closed 2026-07-22). FDA Epitalon briefing document: fda.gov/media/193345/download. FDA's pre-meeting briefing recommends that Epitalon not be added to the Section 503A Bulks List, citing that the substance is not well characterized, has little or no human efficacy evidence for the nominated routes, has insufficient human safety data, and carries unassessed immunogenicity risk.
6. Mavrych V, Shypilova K, Bolgova O. (2026). Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in Aging, 7:1790247. doi: 10.3389/fragi.2026.1790247.(PMID 42021992)

• Pinealon — discussed together in this entry's stacks section
• Bronchogen — same mechanism class
• Cardiogen — same mechanism class
• Cartalax — same mechanism class
• Chonluten — same mechanism class
• Cortagen — same mechanism class